Menu Close
Close
Apply Now
Apply Now →

Stem Cell Therapy for COPD and Pulmonary Conditions

Regenerative Medicine Treatment for Respiratory Care

A physician-supervised approach to supporting lung tissue health and airway function in patients with chronic pulmonary conditions, including COPD, emphysema, and chronic bronchitis. As a stem cell treatment for COPD, all protocols are individualized and require medical evaluation.
Start your evaluation

Addressing Inflammatory Mechanisms of Chronic Pulmonary Lung Disease

UC-MSC and UC-MSC-derived exosome therapies use the regenerative properties of umbilical cord-derived mesenchymal stem cells. These cells have been studied for their capacity to modulate immune responses and support tissue homeostasis in damaged pulmonary environments.

For patients with chronic inflammatory lung disease such as COPD, this biological profile may offer a complementary approach to the underlying disease mechanisms, not a replacement for the inhaled therapies, oxygen, or pulmonary rehabilitation a pulmonologist has prescribed. All protocols are individualized and administered under physician supervision.

stem cells pulmonary care

A multifaceted approach to alleviating COPD symptoms

Research suggests the combined effects of UC-MSC and exosome therapies may address the inflammatory components of chronic pulmonary disease. Evidence varies by condition and remains an area of active investigation.

UC-MSCs secrete anti-inflammatory mediators that may help modulate immune activity in the airways. In conditions such as COPD, this mechanism is being studied for its potential to support symptom management. Effects on disease progression are subject to ongoing research and vary by individual.

COPD and related inflammatory lung diseases involve dysregulation of immune signaling pathways. UC-MSCs may support immune regulation by modulating the activity of pro-inflammatory cells. This is an area of active clinical investigation.

Chronic pulmonary inflammation can contribute to fibrotic changes in lung tissue. UC-MSCs have been studied for their potential to reduce fibrotic signaling; if demonstrated in individual cases, this may support the preservation of pulmonary tissue integrity over time.

Early research and clinical observations suggest that certain bioactive factors released by UC-MSCs may support bronchial muscle relaxation, potentially contributing to improved airway comfort in patients with bronchoconstriction. Evidence is preliminary and individual responses vary. See our Resource Center for supporting references.

Pulmonary Conditions Being Studied with UC-MSC and Exosome Therapies

UC-MSC and exosome protocols are being studied across a range of chronic pulmonary conditions. The list below reflects areas of clinical investigation and the conditions the medical team evaluates. It is not a claim of treatment outcome, suitability depends on diagnosis, disease stage, lung function testing, and overall health.

Chronic Obstructive Pulmonary Disease (COPD) As a stem cell therapy for COPD approach, UC-MSC protocols are studied primarily for their anti-inflammatory and immunomodulatory signaling. COPD involves persistent airway inflammation alongside structural change, and the research interest is in the inflammatory component. Patients continue prescribed bronchodilators, inhaled corticosteroids, and supplemental oxygen unless their pulmonologist directs otherwise.

Stem cell therapy for emphysema research focuses on the inflammatory environment surrounding alveolar damage. Alveolar destruction in emphysema is not currently considered reversible, and no protocol should be presented as restoring lost lung structure. Research interest is in the surrounding tissue environment and disease-related inflammation.

Persistent airway inflammation and mucus hypersecretion characterize chronic bronchitis. UC-MSC anti-inflammatory signaling is the mechanism most directly relevant, and is studied for its potential effect on the airway environment.

As a stem cell therapy for pulmonary fibrosis approach, UC-MSC protocols are studied for their effect on fibrotic signaling pathways, an area of significant research attention, given how limited conventional options are for idiopathic pulmonary fibrosis (IPF). Evidence remains early-stage, disease stage matters considerably, and candidacy is assessed conservatively.

Patients with persistent respiratory symptoms and imaging findings following viral illness, including post-COVID lung involvement, represent one of the more recently studied applications, largely because of the inflammatory and fibrotic mechanisms shared with the conditions above.

UC-MSC immunomodulatory signaling is studied in the context of inflammatory airway conditions more broadly. Suitability depends heavily on how well the condition is controlled with conventional therapy and on the individual clinical picture.

How Regenerative Protocols Fit Alongside Standard Pulmonary Care

Most patients arrive already under pulmonology care. The point of the table below is to show where a regenerative protocol sits relative to that care, as a complementary option to discuss with your physician, never as a substitute for prescribed treatment.

Approach What it does What to keep in mind
Bronchodilators Open airways, relieve shortness of breath Essential symptom control. Does not address underlying inflammation
Inhaled corticosteroids Reduce airway inflammation Effective for many patients. Systemic side effects are possible with long-term use
Pulmonary rehabilitation Improves exercise capacity and breathing efficiency Consistently improves quality of life. Progress can plateau
Oxygen therapy Supports blood oxygenation in advanced disease Supportive and ongoing. Often permanent
Surgical options and transplant Volume reduction or organ replacement in selected cases Narrow eligibility, with significant risk
UC-MSC + exosome protocols Studied for effects on airway inflammation and immune regulation Investigational. Physician evaluation required to confirm candidacy

Patients continue their prescribed inhalers, oxygen, and rehabilitation program before, during, and after a regenerative protocol. Nothing on this page should be read as a reason to reduce or stop prescribed pulmonary treatment. That decision belongs to your treating pulmonologist.

Am I a candidate? Candidacy depends on diagnosis, lung function testing (spirometry and related measures), disease stage, current treatment, smoking status, and overall health. Advanced disease with significant structural loss, or an active infection, may make a protocol inappropriate. Some patients who inquire are told a protocol isn’t suitable for their situation. That determination is made through full physician evaluation during the CARE process, not by self-assessment.

Treatments rooted in scientific research

UC-MSC

UC-MSCs are multipotent stromal cells with immunomodulatory and tissue-supportive properties. In pulmonary disease, they are being studied for their potential to reduce airway inflammation, modulate immune cell activity, and support the integrity of lung tissue.

UC-MSC Derived Exosomes

Exosomes are nanoscale vesicles released by UC-MSCs, carrying proteins, growth factors, and RNA involved in cell-to-cell communication. Think of them as messengers. In pulmonary applications, they’re studied for their potential to reach damaged airway tissue and support immune regulation and repair signaling.

UC-MSC protocols are designed to support tissue environments where chronic inflammation and structural damage are present. In the pulmonary context, UC-MSCs administered intravenously alongside UC-MSC-derived exosomes may support airway tissue health and immune regulation.

Why Patients Travel for UC-MSC Pulmonary Protocols

Allogeneic UC-MSC protocols of this kind are not currently available through US clinics. OmniStem’s facility in Punta Cana, Dominican Republic is approximately 90 minutes by air from Miami, with direct flights from major Eastern US cities. Patients using supplemental oxygen should raise travel logistics during evaluation, the care team coordinates these arrangements as part of protocol planning.

Frequently Asked Questions

Umbilical cord–derived mesenchymal stromal cells (UC-MSCs) are being studied for their ability to calm inflammation and support tissue repair in the lungs. In conditions such as COPD, where chronic inflammation and tissue damage play a central role, UC-MSCs may help create a healthier environment in the airways by reducing immune overreaction and supporting regeneration. Compared to older stem cell sources, UC-MSCs are younger, biologically active, and less likely to trigger an immune response.

Exosomes are microscopic vesicles released by UC-MSCs that carry proteins, growth factors, and RNA. Their small size allows them to cross biological barriers and reach damaged lung tissue, where they may help regulate immune activity, reduce inflammation, and support repair processes. Rather than replacing cells, exosomes act as messengers that encourage the body's own cells to function differently.

Clinical studies and early patient experiences suggest that UC-MSC and exosome therapies are generally well tolerated. The risk of immune rejection is very low due to their properties and careful laboratory processing. Possible side effects include temporary fatigue, soreness, or mild inflammation as the body responds to the infusion. As with any medical therapy, rare complications are possible, and all patients undergo detailed screening before treatment.

No. UC-MSC and exosome protocols are evaluated as a complementary approach alongside pulmonology-directed care, not as a replacement for it. Patients continue prescribed bronchodilators, inhaled corticosteroids, supplemental oxygen, and pulmonary rehabilitation unless their treating pulmonologist directs otherwise. Any change to prescribed respiratory medication is a decision for the physician managing your condition.

Structural lung damage, the alveolar destruction seen in emphysema, for example — is not currently considered reversible, and no clinic should claim otherwise. What UC-MSC and exosome therapies are being studied for is narrower: the inflammatory and immune environment that contributes to ongoing damage. Some patients report changes in breathing comfort and exercise tolerance; these are individual, not guaranteed, and assessed clinically over time.

stem cells for lungs disease

UC-MSC and Exosomes Treatment

Discover how umbilical cord mesenchymal stem cells can help reduce lung inflammation and support your respiratory healing.

Start your Evaluation

Your case.

In our hands.

Within 48 hours.

A physician on the OmniStem medical team will review your clinical profile and prepare an initial assessment. What follows is a medical conversation.

Your clinical profile   2 MIN

A brief summary of your health context. The medical team uses this to prepare before your first conversation.

Physician review   48 H

Dr. Montoya or a member of the medical team evaluates your profile individually.

A clinical conversation

Your history, your priorities, and what a protocol designed around your clinical profile might include.

No obligation

The case review is informational. The only timeline that matters is yours.

Step 1

A few questions to begin

These help the medical team understand whether OmniStem’s protocols are appropriate for your situation before we speak.

Check Access 2.0

What is your primary area of health concern?

Select up to three options that best describe your concerns.

Discuss your clinical profile with our medical team

A physician on the OmniStem medical team will review your pulmonary health profile and discuss whether a regenerative protocol may be appropriate for your clinical situation.

Start your evaluation